Lantern Pharma is trading at $0.61, down 5.44% during the October 20, 2026 regular session; no company-specific explanation for the decline is confirmed.
- The latest company investor-relations release found was dated October 8.
- A patent allowance for LP-284 was reported October 19, but available sources do not connect it to the decline.
- Biotech-sector context is positive, while broader market indications are mixed; neither establishes a clear explanation.